Remynd raises €3.5M to get novel Alzheimer’s program back on track

Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity problems and raising €3.5 million (US$4 million) from the Alzheimer’s Drug Discovery Foundation. The money will support a…

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

1. BioWorld Articles 6h ago
   Remynd raises €3.5M to get novel Alzheimer’s program back on track ↗